DARA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DARA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
DARA Biosciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for DARA Biosciences's Piotroski F-Score or its related term are showing as below:
The historical data trend for DARA Biosciences's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DARA Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec05 | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | |||||||||||
Piotroski F-Score | Get a 7-Day Free Trial | 2.00 | 3.00 | 4.00 | 4.00 | 5.00 |
DARA Biosciences Quarterly Data | ||||||||||||||||||||
Dec10 | Mar11 | Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | |
Piotroski F-Score | Get a 7-Day Free Trial | 4.00 | 5.00 | 4.00 | 5.00 | 5.00 |
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Sep15) TTM: | Last Year (Sep14) TTM: |
Net Income was -1.65 + -3.151 + -2.684 + -2.698 = $-10.18 Mil. Cash Flow from Operations was -1.933 + -2.154 + -2.795 + -2.292 = $-9.17 Mil. Revenue was 0.718 + 0.652 + 0.991 + 1.181 = $3.54 Mil. Gross Profit was 0.545 + 0.504 + 0.73 + 0.94 = $2.72 Mil. Average Total Assets from the begining of this year (Sep14) to the end of this year (Sep15) was (18.532 + 17.752 + 14.758 + 11.877 + 9.683) / 5 = $14.5204 Mil. Total Assets at the begining of this year (Sep14) was $18.53 Mil. Long-Term Debt & Capital Lease Obligation was $0.02 Mil. Total Current Assets was $6.23 Mil. Total Current Liabilities was $3.44 Mil. |
Net Income was -2.354 + -2.658 + -2.583 + -2.11 = $-9.71 Mil. Revenue was 0.182 + 0.161 + 0.409 + 0.598 = $1.35 Mil. Gross Profit was 0.114 + 0.108 + 0.318 + 0.472 = $1.01 Mil. Average Total Assets from the begining of last year (Sep13) to the end of last year (Sep14) was (7.367 + 7.988 + 11.442 + 20.333 + 18.532) / 5 = $13.1324 Mil. Total Assets at the begining of last year (Sep13) was $7.37 Mil. Long-Term Debt & Capital Lease Obligation was $0.02 Mil. Total Current Assets was $14.89 Mil. Total Current Liabilities was $2.26 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
DARA Biosciences's current Net Income (TTM) was -10.18.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
DARA Biosciences's current Cash Flow from Operations (TTM) was -9.17.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Sep14) |
= | -10.183 | / | 18.532 | |
= | -0.54948198 |
ROA (Last Year) | = | Net Income | / | Total Assets (Sep13) |
= | -9.705 | / | 7.367 | |
= | -1.31736121 |
DARA Biosciences's return on assets of this year was -0.54948198. DARA Biosciences's return on assets of last year was -1.31736121.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
DARA Biosciences's current Net Income (TTM) was -10.18. DARA Biosciences's current Cash Flow from Operations (TTM) was -9.17.
==> -9.17 > -10.18 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Sep15) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Sep14 to Sep15 |
= | 0.016 | / | 14.5204 | |
= | 0.0011019 |
Gearing (Last Year: Sep14) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Sep13 to Sep14 |
= | 0.024 | / | 13.1324 | |
= | 0.00182754 |
DARA Biosciences's gearing of this year was 0.0011019. DARA Biosciences's gearing of last year was 0.00182754.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Sep15) | = | Total Current Assets | / | Total Current Liabilities |
= | 6.225 | / | 3.44 | |
= | 1.80959302 |
Current Ratio (Last Year: Sep14) | = | Total Current Assets | / | Total Current Liabilities |
= | 14.893 | / | 2.264 | |
= | 6.57818021 |
DARA Biosciences's current ratio of this year was 1.80959302. DARA Biosciences's current ratio of last year was 6.57818021.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
DARA Biosciences's number of shares in issue this year was 19.756. DARA Biosciences's number of shares in issue last year was 19.462.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 2.719 | / | 3.542 | |
= | 0.7676454 |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 1.012 | / | 1.35 | |
= | 0.74962963 |
DARA Biosciences's gross margin of this year was 0.7676454. DARA Biosciences's gross margin of last year was 0.74962963.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Sep14) |
= | 3.542 | / | 18.532 | |
= | 0.19112886 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Sep13) |
= | 1.35 | / | 7.367 | |
= | 0.18324963 |
DARA Biosciences's asset turnover of this year was 0.19112886. DARA Biosciences's asset turnover of last year was 0.18324963.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 0 | + | 0 | + | 1 | + | 1 | + | 1 | + | 0 | + | 0 | + | 1 | + | 1 | |
= | 5 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
DARA Biosciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.
DARA Biosciences (NAS:DARA) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of DARA Biosciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
David Drutz | director, officer: Executive Chairman and CMO | 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
David L. Tousley | officer: CFO | 14610 PAWNEE LANE, LEAWOOD KS 66224 |
Gail Lieberman | director | 175 EAST 79TH STREET, APT. 4D, NEW YORK NY 10075 |
Paul John Richardson | director | 17 COUNTRY OAKS ROAD, LEBANON NJ 08833 |
Steve Gorlin | director | 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541 |
Ann A Rosar | officer: Vice President Finance | C/O 801 CAPITOLA DRIVE, DURHAM NC 27713 |
John C Thomas | director | 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
Geert Cauwenbergh | director | 1 STULTS DRIVE, PLAINSBORO NJ 08536 |
Kurt M Eichler | director | C/O SPRING BANK PHARMACEUTICALS, INC., STE S-7, MILFORD MA 01757 |
Hamilton Jordan | director | |
Stuart C Mcwhorter | director | 113 SEABOARD LANE, FRANKLIN TN 37067 |
Timothy J Barberich | director | 40 ELM ST, CONCORD MA 01752 |
Michael P Duffy | officer: SVP, GC and Secretary | C/O POINT THERAPEUTICS INC, 125 SUMMER STREET SUITE 1840, BOSTON MA 02110 |
Richard J Benjamin | director | 15 WHITE PINE ROAD, NEWTON MA 02464 |
Larry G Pickering | director | 26130 MANDEVILLA DRIVE, BONITA SPRINGS FL 34134 |
From GuruFocus
By gurufocus • 05-16-2009
By gurufocus 10qk • 05-14-2010
By gurufocus • 08-14-2009
By gurufocus 10qk • 11-13-2009
By gurufocus 10qk • 08-13-2010
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.